Development of Simple, Rapid & High-Throughput Glycoanalytics for Biopharmaceuticals.

While biotherapeutics offer potential treatments for some of the most debilitating diseases the development and manufacture of these potentially life changing treatments is risky, technically challenging and expensive. This program will combine GlycoSeLect UK Ltd's glycosylation recognition technology with ForteBio Pall Life Science's unique BLI biosensor based analytical platform technology. This will create a novel analytical platform that will enable rapid and high-throughput analysis of biotherapeutic product glycosylation, a critical product quality attribute that impacts on the efficacy and safety of these therapeutic molecules. This new glycoanalytical platform can be deployed throughout the biotherapeutic development pipeline, and in manufacturing processes, to increase the efficiency and deliver significant cost savings. By working in partnership with Allergan Biologics Ltd, a leading biotherapeutic developer and manufacture, and the Centre for Process Innovation (CPI) this project will demonstrate the value of this new glycoanalytical platform for the rapid glycoanalysis of biotherapeutic products to support the development and manufacture of these important therapeutic products.